keyword
MENU ▼
Read by QxMD icon Read
search

Hyperthermic intraperitoneal chemotherapy

keyword
https://www.readbyqxmd.com/read/29332351/cytoreductive-surgery-and-hyperthermic-intraperitenoal-chemotherapy-hipec-for-colorectal-and-appendiceal-carcinomas-with-peritoneal-carcinomatosis
#1
Nicolaos Pallas, Christina Karamveri, Dimitrios Kyziridis, Christos Hristakis, Vasileios Kyriakopoulos, Apostolos Kalakonas, Dimitrios Vaikos, Antonios-Apostolos K Tentes
PURPOSE: Cytoreductive surgery combined with intraperitoneal chemotherapy has been established as the standard treatment for selected patients with peritoneal malignancy. The purpose of the study was the presentation of the 10- year experience with cytoreductive surgery and intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal and appendiceal origin. METHODS: Clinical and histopathological variables were retrospectively reviewed in a prospectively maintained database...
November 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29331663/a-multi-center-randomized-trial-to-evaluate-hematologic-toxicities-after-hyperthermic-intraperitoneal-chemotherapy-with-oxaliplatin-or-mitomycin-in-patients-with-appendiceal-tumors
#2
Edward A Levine, Konstantinos I Votanopoulos, Perry Shen, Greg Russell, Joyce Fenstermaker, Paul Mansfield, David Bartlett, John H Stewart
BACKGROUND: Appendiceal cancer is a rare disease, which has proven difficult to study in prospective trials. Cytoreductive surgery with HIPEC is an established therapy for peritoneal dissemination from appendiceal cancer. The optimal chemotherapeutic agent to use in the HIPEC is not clear. Mitomycin has long been the utilized, however our previous phase I experience, and European retrospective studies suggest oxaliplatin as an alternative. Therefore, we initiated a multicenter randomized trial to compare mitomycin to oxaliplatin HIPEC for appendiceal cancer...
January 10, 2018: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/29319729/effects-of-nivolumab-in-peritoneal-carcinamatosis-of-malign-melanoma-in-mouse-model
#3
Ozgul Duzgun, Inanc Samil Sarici, Serkan Gokcay, Kivilcim Eren Ates, Mehmet Bertan Yılmaz
PURPOSE: To evaluate the efficacy of nivolumab and comparison with dacarbazine (DTIC) on peritoneal carcinomatosis of malignant melanoma in mouse model. METHODS: Mouse skin melanoma cells was injected under the capsule of the peritoneal surface in the left side of the abdomen. On postoperative day ten, mouses randomised into three groups. Group 1: Control, Group 2: HIPEC (Hyperthermic intraperitoneal chemotherapy) with DTIC and Group 3: HIPEC with Nivolumab. After the sacrification on postoperative day fifteen, peritoneum evaluated macroscopically and histopathologically by using peritoneal regression grading score (PRGS)...
December 2017: Acta Cirúrgica Brasileira
https://www.readbyqxmd.com/read/29316159/safety-of-extraperitoneal-rectal-resection-and-ileo-or-colorectal-anastomosis-without-loop-ileostomy-in-patients-with-peritoneal-metastases-treated-with-crs-and-hipec
#4
Andreas Brandl, Wieland Raue, Felix Aigner, Maria Clara Arroyave, Johann Pratschke, Beate Rau
AIM: Extraperitoneal rectal resection combined with complete peritonectomy of the pelvis in patients with peritoneal metastases is associated with a high rate of morbidity and mortality due to anastomotic leakage (AL). Therefore, many centers tend to perform loop ileostomy to reduce the clinical impact of AL. The aim of this study was to analyze the need for protective stoma creation in this patient group to avoid major complications and mortality in the case of AL. METHOD: We analyzed 53 patients who underwent extraperitoneal rectal resection from 409 consecutive patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) at our department between January 1997 and December 2016...
January 6, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/29313146/long-term-quality-of-life-after-cytoreductive-surgery-and-heated-intraperitoneal-chemotherapy-for-pseudomyxoma-peritonei-a-prospective-longitudinal-study
#5
Adam T Stearns, Lee Malcomson, Grant Punnett, Haytham Abudeeb, Omer Aziz, Chelliah R Selvasekar, Paul E Fulford, Malcolm S Wilson, Andrew G Renehan, Sarah T O'Dwyer
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are an established treatment for pseudomyxoma peritonei (PMP), but it is a major surgical procedure and may be associated with long-term morbidity. To date, health-related quality-of-life (HRQL) data among survivors are lacking. METHODS: A two-period qualitative study investigated patients undergoing CRS-HIPEC for PMP at a national peritoneal tumor center between 2003 and 2011...
January 8, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29302727/implications-of-stoma-formation-as-part-of-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#6
H Jacoby, Y Berger, L Barda, N Sharif, Y Zager, A Lebedyev, M Gutman, A Hoffman
BACKGROUND: Formation of protective stoma as part of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) may be an effective tool in reducing anastomotic leak incidence. Our aim was to evaluate the incidence and implications of stoma formation during CRS-HIPEC and to examine whether a creation of protective stoma reduces the postoperative morbidity. METHODS: A cohort retrospective analysis of all CRS-HIPEC procedures performed between 2004 and 2016 was conducted...
January 4, 2018: World Journal of Surgery
https://www.readbyqxmd.com/read/29288614/laparoscopic-hipec-for-peritoneal-carcinomatosis-from-gastric-cancer-technique-and-early-outcomes-of-our-first-cases
#7
Irina Bălescu, Daniela Godoroja, Mircea Gongu, Victor Tomulescu, Cătălin Copăescu
Gastric cancer remains one of the most aggressive malignancies, being associated with very poor therapeutic outcomes, especially in the advanced disease patients. Due to this evidence, finding a better treatment, a better control and higher survival rates is the current scientific focus of the medical community. Once the benefits of cytoreductive surgery in association with intraperitoneal hyperthermy (HIPEC) have been widely demonstrated in patients presenting peritoneal carcinomatosis from colorectal or ovarian origin,attention was focused on the possible benefit of this method in patients diagnosed with peritoneal carcinomatosis with gastric origin...
November 2017: Chirurgia
https://www.readbyqxmd.com/read/29288288/pci-is-not-predictive-of-survival-after-complete-crs-hipec-in-peritoneal-dissemination-from-high-grade-appendiceal-primaries
#8
Konstantinos Ioannis Votanopoulos, David Bartlett, Brendan Moran, Choudry M Haroon, Greg Russell, James F Pingpank, Lekshmi Ramalingam, Chandrakumaran Kandiah, Konstantinos Chouliaras, Perry Shen, Edward A Levine
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is a treatment option in patients with carcinomatosis from high-grade appendiceal (HGA) primaries. It is unknown if there is a Peritoneal Carcinomatosis Index (PCI) upper limit above which a complete CRS/HIPEC does not assure long-term survival. METHODS: Retrospective analysis from three centers was performed. The PCI was used to grade volume of of disease. Survival in relation to PCI was studied on patients with complete cytoreduction...
December 29, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29286576/cytoreductive-surgery-and-hyperthermic-intraperitoneal-perfusion-with-chemotherapy-in-children-with-peritoneal-tumor-spread-a-french-nationwide-study-over-14-years
#9
Aurélien Scalabre, Pascale Philippe-Chomette, Guillaume Passot, Daniel Orbach, Dominique Elias, Nadège Corradini, Laurence Brugières, Simon Msika, Marc-David Leclair, Solène Joseph, Cécile Brigand, François Becmeur, Christine Soler, Denis Pezet, Johan Gagniere, Olivier Glehen, Sabine Sarnacki
BACKGROUND: Efficacy and role of cytoreductive surgery (CRS) and hyperthermic peritoneal perfusion with chemotherapy (HIPEC) remain poorly documented in pediatric tumors. METHODS: This retrospective national study analyzed all pediatric patients with peritoneal tumor spread treated by CRS and HIPEC as part of a multimodal therapy in France from 2001 to 2015. RESULTS: Twenty-two patients (nine males and 13 females) were selected. The median age at diagnosis was 14...
December 29, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29285641/core-body-temperature-but-not-intraabdominal-pressure-predicts-postoperative-complications-following-closed-system-hyperthermic-intraperitoneal-chemotherapy-hipec-administration
#10
M Goldenshluger, D Zippel, A Ben-Yaacov, J Dux, T Yalon, A Zendel, S Rayman, E Mor, H Berkenstadt, H Fogel-Grinvald, M Ventorrero, A Nissan
BACKGROUND: Hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery (CRS), performed using closed-abdomen technique (CAT), may affect intraabdominal pressure (IAP). High IAP may increase postoperative complications due to decreased venous return and hypoperfusion to vital organs. Elevated core body temperature (CBT) may cause multiorgan dysfunction. Low IAP or CBT could result in suboptimal HIPEC and potentially translate into early disease recurrence. The aim of the present study is to identify possible correlations between IAP or CBT and postoperative complications...
December 29, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29282602/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-the-elderly-is-it-reasonable-a-meta-analysis
#11
Johan Gagnière, Julie Veziant, Bruno Pereira, Denis Pezet, Bertrand Le Roy, Karem Slim
BACKGROUND: Whether cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is safe and worthwhile for elderly patients remains unclear. This meta-analysis of outcomes after CRS plus HIPEC for the elderly aimed to generate a higher level of evidence and precise indications for these patients. METHODS: A systematic literature search for studies reporting postoperative outcomes after CRS plus HIPEC for elderly patients was performed in the MEDLINE, Cochrane Central Register of Controlled Trials, ClinicalTrials...
December 28, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29282600/cytoreductive-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-for-patients-with-peritoneal-metastases-from-endometrial-cancer
#12
Tommaso Cornali, Paolo Sammartino, Nikolaos Kopanakis, Athina Christopoulou, Marialuisa Framarino Dei Malatesta, Elias Efstathiou, Alessandra Spagnoli, Antonio Ciardi, Daniele Biacchi, John Spiliotis
BACKGROUND: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: This study analyzed clinical, pathologic, and treatment data for patients with peritoneal metastases from EC who underwent CRS plus HIPEC at two tertiary centers. The outcome measures were morbidity, overall survival (OS), and progression-free survival (PFS) during a median 5 year follow-up period...
December 27, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29277807/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-elderly-patients-complete-cytoreduction-is-feasible-and-crucial-for-improved-survival-despite-high-carcinomatosis-index
#13
Samer A Naffouje, George I Salti
BACKGROUND: We aimed to study the surgical outcomes of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in elderly patients, and investigate whether the pursuit of complete cytoreduction implies a survival benefit despite a high peritoneal carcinomatosis index (PCI). PATIENTS AND METHODS: All CRS and HIPEC procedures performed for patients with peritoneal surface malignancy (PSM) ≥65 years old between 2005-2017 were included. A control group comprising patients 60-64 years old who underwent CRS and HIPEC over the same period was also selected for comparison of characteristics and outcomes...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29277751/regimens-of-intraperitoneal-chemotherapy-for-peritoneal-carcinomatosis-from-colorectal-cancer
#14
REVIEW
Koji Murono, Kazushige Kawai, Keisuke Hata, Shigenobu Emoto, Manabu Kaneko, Kazuhito Sasaki, Takeshi Nishikawa, Kensuke Otani, Toshiaki Tanaka, Hiroaki Nozawa
Although systemic chemotherapy has been improved, peritoneal carcinomatosis remains a factor of poor prognosis in patients with colorectal cancer. In order to achieve a higher drug concentration in the peritoneal cavity, intraperitoneal chemotherapy has been performed. However, the optimal regimen for intraperitoneal chemotherapy has not been determined. In this review of intraperitoneal chemotherapy for colorectal cancer, we summarize regimens of hyperthermic intraperitoneal chemotherapy (HIPEC) and other intraperitoneal chemotherapy modalities, such as early postoperative intraperitoneal chemotherapy (EPIC) and sequential postoperative intraperitoneal chemotherapy (SPIC)...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29260418/is-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-justified-for-biphasic-variants-of-peritoneal-mesothelioma-outcomes-from-the-peritoneal-surface-oncology-group-international-registry
#15
Konstantinos I Votanopoulos, Paul Sugarbaker, Marcello Deraco, David Morris, Olivier Glehen, Dominique Elias, Michele De Simone, Manuela Robella, Bruno Heyd, Shigeki Kusamura, Dario Baratti, Konstantinos Chouliaras, Greg Russell, Perry Shen, Edward A Levine
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has dramatically improved the survival of patients with epithelioid peritoneal mesothelioma. It is unknown if CRS/HIPEC is indicated for the more aggressive biphasic mesothelioma variant. METHODS: A retrospective analysis of the Peritoneal Surface Oncology Group International (PSOGI) registry including data from 33 centers was performed. Survival was reviewed based on mesothelioma type, completion of cytoreduction, and volume of disease...
December 19, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29260417/the-comprehensive-complication-index-a-new-measure-of-the-burden-of-complications-after-hyperthermic-intraperitoneal-chemotherapy
#16
Sinziana Dumitra, Michael O'Leary, Mustafa Raoof, Mark Wakabayashi, Thanh H Dellinger, Ernest S Han, Stephen J Lee, Byrne Lee
BACKGROUND: Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) are complex surgeries with multiple comorbidities. The Clavien-Dindo classification (CDC) is the most commonly used method to report surgical morbidity, but limits it to the highest-grade complication. The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all 30-day complications and their treatment after abdominal surgery. The aim of this study is to assess the CCI's validity in the HIPEC patient population...
December 19, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29258720/safety-of-intraperitoneal-mitomycin-c-versus-intraperitoneal-oxaliplatin-in-patients-with-peritoneal-carcinomatosis-of-colorectal-cancer-undergoing-cytoreductive-surgery-and-hipec
#17
W J van Eden, N F M Kok, K Woensdregt, A D R Huitema, H Boot, A G J Aalbers
BACKGROUND: Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). There is an ongoing international debate about which intraperitoneal chemotherapeutic agent is preferred, Mitomycin C (MMC) or oxaliplatin. We questioned whether the type of chemotherapeutic agent influenced postoperative complication rates or short-term survival. METHODS: In this retrospective cohort study patients with colorectal PC who underwent CRS-HIPEC between January 2010 and December 2016 were included...
November 15, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29249869/short-term-postoperative-cognitive-dysfunction-and-inflammatory-response-in-patients-undergoing-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-a-pilot-study
#18
Hui Yu, Rui Dong, Yayuan Lu, Xi Yang, Chang Chen, Zongze Zhang, Mian Peng
Objectives: To assess the association between short-term postoperative cognitive dysfuction (POCD) and inflammtory response in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Design: A prospective cohort study. Setting: University medical centre. Participants: Fifty-one adult patients who had undergone CRS-HIPEC and twenty control participants. Measurements: The inflammatory marker levels in plasma and cognitive function were measured...
2017: Mediators of Inflammation
https://www.readbyqxmd.com/read/29242018/current-practice-in-cytoreductive-surgery-and-hipec-for-metastatic-peritoneal-disease-spanish-multicentric-survey
#19
Rafael Morales-Soriano, Neus Esteve-Pérez, Juan José Segura-Sampedro, Pedro Cascales-Campos, Pedro Barrios
INTRODUCTION: Radical Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), has been proposed as the current standard of treatment for metastatic peritoneal disease by several tumors. Despite its widely utilization, there seems to be a great variability in their organization, clinical practice, and safety among centers. AIM OF THE STUDY: To obtain updated information on clinical practice in different perioperative areas of the CRS-HIPEC...
December 6, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29238881/peritoneal-carcinomatosis-of-urachus-origin-treated-by-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec-an-international-registry-of-36-patients
#20
Frederic Mercier, Guillaume Passot, Laurent Villeneuve, Edward A Levine, Yutaka Yonemura, Diane Goéré, Paul H Sugarbaker, Christelle Marolho, David L Bartlett, Olivier Glehen
PURPOSE: Peritoneal carcinomatosis or pseudomyxoma peritonei from urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers...
December 13, 2017: Annals of Surgical Oncology
keyword
keyword
23492
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"